1-2 of 2
Christopher Guise
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial

Adam V. Patterson, Shevan Silva, Christopher Guise, Maria Abbattista, Matthew Bull, Huai-Ling Hsu, Charles Hart, Jessica Sun, Angus Grey, Amir Ashoorzadeh, Robert Anderson, Jeff B. Smaill
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 5358.
https://doi.org/10.1158/1538-7445.AM2015-5358
Published: 01 August 2015
View article titled, Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial
Journal Articles

Generation of Escherichia Coli Nitroreductase Mutants Conferring Improved Cell Sensitization to the Prodrug CB1954

Jane I. Grove, Andrew L. Lovering, Christopher Guise, Paul R. Race, Christopher J. Wrighton, Scott A. White, Eva I. Hyde, Peter F. Searle
Journal: Cancer Research
Cancer Res (2003) 63 (17): 5532–5537.
Published: 18 September 2003
View article titled, Generation of <em>Escherichia Coli</em> Nitroreductase Mutants Conferring Improved Cell Sensitization to the Prodrug CB1954
Open the PDF for Generation of <em>Escherichia Coli</em> Nitroreductase Mutants Conferring Improved Cell Sensitization to the Prodrug CB1954 in another window